DouglasDonaldRossMD

PubMed

• 7 citations
  Metformin and Androgen Receptor-Axis-Targeted (ARAT) Agents Induce Two PARP-1-Dependent Cell Death Pathways in Androgen-Sensitive Human Prostate Cancer Cells.
  Yi Xie, Linbo Wang, Mohammad Afnan Khan, Anne W. Hamburger, Wei Guang, Antonino Passaniti, Kashif M. Munir, Douglas D. Ross, Michael Dean, Arif Hussain> ;Cancers. 2021 Feb 5
• 11 citations
  Death-associated Protein Kinase-1 Expression and Autophagy in Chronic Lymphocytic Leukemia Are Dependent on Activating Transcription Factor-6 and CCAAT/Enhancer-bindin...
  Padmaja Gade, Amy S. Kimball, Angela C. DiNardo, Priyamvada Gangwal, Douglas D. Ross, H. Scott Boswell, Susan Keay, Dhananjaya V. Kalvakolanu> ;The Journal of Biological Chemistry. 2016 Oct 14
• 1 citations
  Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1.
  Karthika Natarajan, Yi Xie, Takeo Nakanishi, Rebecca S. Moreci, Pancharatnam Jeyasuria, Arif Hussain, Douglas D. Ross> ;Journal of Visualized Experiments. 2016 May 27
• 14 citations
  Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen wi...
  Yi Xie, Takeo Nakanishi, Karthika Natarajan, Lowell Safren, Anne W. Hamburger, Arif Hussain, Douglas D. Ross> ;Biochimica Et Biophysica Acta. 2015 Mar 1
• 1 citations
  Concomitant bone marrow involvement by plasma cell myeloma and primary myelodysplastic syndrome with biclonal complex chromosome anomalies
  Nahid M. Nanaji, Qing C. Chen, Zeba N. Singh, Douglas D. Ross, Ari H. Elman, Ying S. Zou> ;Leukemia & Lymphoma. 2015 Jan 14
• 4 citations
  Bcrp1 transcription in mouse testis is controlled by a promoter upstream of a novel first exon (E1U) regulated by steroidogenic factor-1
  Yi Xie, Karthika Natarajan, Kenneth S. Bauer, Takeo Nakanishi, William T. Beck, Rebecca S. Moreci, Pancharatnam Jeyasuria, Arif Hussain, Douglas D. Ross> ;Biochimica Et Biophysica Acta. 2013 Nov 2
• 7 citations
  Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells
  Devendra K Hiwase, Verity A Saunders, Eva Nievergall, Douglas D. Ross, Deborah L. White, Timothy P. Hughes> ;Haematologica. 2013 Jun 1
• 40 citations
  Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk ...
  Ivana Gojo, Ming Tan, Hong-Bin Fang, Mariola Sadowska, Rena G. Lapidus, Maria R. Baer, Jan H. Beumer, Bean N. Anyang, Rakesh K. Srivastava, Igor Espinoza-Delgado, Doug...> ;Clinical Cancer Research. 2013 Apr 1
• 18 citations
  Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells.
  Alex Wu, Pooja Dalvi, Xiaoli Lu, Mingdong Yang, David S. Riddick, Jason Matthews, Charles V. Clevenger, Douglas D. Ross, Patricia A. Harper, Shinya Ito> ;Molecular Pharmacology. 2013 Feb 1
• 188 citations
  Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
  Takeo Nakanishi, Douglas D. Ross> ;Chinese Journal of Cancer. 2012 Feb 1
• 294 citations
  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.
  Karthika Natarajan, Yi Xie, Maria R. Baer, Douglas D. Ross> ;Biochemical Pharmacology. 2012 Apr 15
• 25 citations
  Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
  Matthew Squires, George Ward, Gordon Saxty, Valerio Berdini, Anne Cleasby, Peter King, Patrick Angibaud, Tim Perera, Lynsey Fazal, Douglas D. Ross, Charlotte Griffiths...> ;Molecular Cancer Therapeutics. 2011 Jul 15
• 15 citations
  Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine
  Karthika Natarajan, Yi Xie, Takeo Nakanishi, William T. Beck, Kenneth S. Bauer, Douglas D. Ross> ;Biochimica Et Biophysica Acta. 2011 Jul 1
• 5 citations
  Creative solution for implementation of experiential, competency-based palliative care training for internal medicine residents
  Douglas D. Ross, Deborah Shpritz, Susan D. Wolfsthal, Ann B. Zimrin, Timothy J. Keay, Hong-Bin Fang, Carl A. Schuetz, Laura M. Stapleton, David E. Weissman> ;Journal of Cancer Education. 2011 May 8
• 14 citations
  Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-5...
  Xiaonan Hou, Fei Huang, Joan M. Carboni, Karen S. Flatten, Yan W. Asmann, Cynthia Ten Eyck, Takeo Nakanishi, Jennifer D. Tibodeau, Douglas D. Ross, Marco M. Gottardis,...> ;Molecular Cancer Therapeutics. 2011 Jan 1
• 85 citations
  Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2).
  Kah Poh Tan, Bernice Wang, Mingdong Yang, Paul C. Boutros, Jane MacAulay, Haibo Xu, Andrew I. Chuang, Kazuhiro Kosuge, Mika Yamamoto, Shinichiro Takahashi, Alex Wu, Do...> ;Molecular Pharmacology. 2010 Aug 1
• 73 citations
  Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative am...
  Xuetao Fan, Douglas D. Ross, Hiroshi Arakawa, Vadivel Ganapathy, Ikumi Tamai, Takeo Nakanishi> ;Biochemical Pharmacology. 2010 Sep 15
• Quotes from Colleagues about Richard F. Bakemeier
  Chuck Kupchella, Milly Haagedoorn, Michael J. Brooks, Arthur M Michalek, Edwn Albert Mirand, Sol Silverman, John T. Vetto, Heather Mercer, Carol Reed Ash, Harold Haile...> ;Journal of Cancer Education. 2010 Jun 1
• 8 citations
  Methods to evaluate transporter activity in cancer.
  Takeo Nakanishi, Douglas D. Ross, Keisuke Mitsuoka> ;Methods in Molecular Biology. 2010 Jan 1
• 37 citations
  Impact of breast cancer resistance protein on cancer treatment outcomes.
  Douglas D. Ross, Takeo Nakanishi> ;Methods in Molecular Biology. 2010 Jan 1
• 47 citations
  Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice
  Sharmila Shankar, Rachel Davis, Karan P. Singh, Razelle Kurzrock, Douglas D. Ross, Rakesh K. Srivastava> ;Molecular Cancer Therapeutics. 2009 Jun 1
• 46 citations
  Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
  Ken Shiozawa, Takeo Nakanishi, Ming Tan, Hong Bin Fang, Wen Chyi Wang, Martin J. Edelman, David Carlton, Ivana Gojo, Edward A. Sausville, Douglas D. Ross> ;Clinical Cancer Research. 2009 Mar 1
• 85 citations
  Progesterone Receptor (PR) Isoforms PRA and PRB Differentially Regulate Expression of the Breast Cancer Resistance Protein in Human Placental Choriocarcinoma BeWo Cells
  Honggang Wang, Eun Woo Lee, Lin Zhou, Peter C.K. Leung, Douglas D. Ross, Jashvant D. Unadkat, Qingcheng Mao> ;Molecular Pharmacology. 2008 Mar 1
• 151 citations
  The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells.
  Yingqiu Xie, Kexin Xu, Douglas E. Linn, Xi Yang, Zhiyong Guo, Hermela Shimelis, Takeo Nakanishi, Douglas D. Ross, Hegang Chen, Ladan Fazli, Martin E. Gleave, Yun Qiu> ;The Journal of Biological Chemistry. 2008 Feb 8
• 12 citations
  Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells.
  Dong I. Lee, Carlota Sumbilla, Myounghee Lee, Chidambaram Natesavelalar, Michael G. Klein, Douglas D. Ross, Giuseppe Inesi, Arif Hussain> ;Archives of Biochemistry and Biophysics. 2007 Aug 1
• Join now to see all

Journal Articles

• Concomitant bone marrow involvement by plasma cell myeloma and primary Myelodysplastic syndrome with biclonal complex chromosome anomalies  
  Nanaji, N.M., Chen, Q.C., Singh, Z., Ross, D.D., Elman, A., Zou, Y.S., Leukemia and Lymphoma, 1/1/2015
• Bcrp1 transcription in mouse testis is controlled by a promoter upstream of a novel first exon (E1U) regulated by steriodogenic factor-1  
  Xie, Y., Natarajan, K., Bauer, K.S., Nakanishi, T., Beck, W.T., Moreci, R.S., Jeyasuria, P., Hussain, A., Ross, D.D., Biochim Biophys Acta Gene Regulatory Mechanisms, 1/1/2013
• Drug efflux by Breast Cancer Resistance Protein (BCRP) is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor...  
  Hou, X., Huang, F., Carboni, J.M., Flatten, K., Asmann, Y.W., Ten Eyck, C., Nakanishi, T., Tibodeau, J.D., Ross, D.D., Gottardis, M.M., Erlichman, C., Kaufmann,, S.H.,..., Mol Cancer Ther, 1/1/2011
• Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signaling  
  Nakanishi, T., Chumsri, S., Khakkpour, N., Brodie, A.H., Leyland-Jones, B., Hamburger, A.W., Ross, D.D., Burger, A.M., British Journal of Cancer, 1/1/2010
• Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: A possible target for combination therapy with antiproliferative ami...  
  Fan, X., Ross, D.D., Ganapathy, V., Tamai, I., Nakanishi T, Biochemical Pharmacology, 1/1/2010
• Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2)  
  Tan, K.P, Wang, B., Yang, M.D., Boutros, P., MacAulay, J., Xu, H., Chuang, A., Kosuge, K., Yamamoto, M., Takahashi, S-IO, Wu, A., Ross, D.D., Ito, S, Molecular Pharmacology, 1/1/2010
• Impact of Breast Cancer Resistance Protein (BCRP/ABCG2) on Cancer Treatment Outcomes  
  Ross, D.D., Nakanishi, T, "Multidrug Resistance in Cancer,” Methods in Mol Biol, University of Pittsburgh Cancer Institute Basic Research Seminar, 1/1/2010
• Preclinical Studies of Vorinostat (Suberoyl­anilide Hydroxamic Acid, SAHA) Combined with Cytosine Arabinoside (ara-C) and Etoposide for Treatment of Acute Leukemias  
  Shiozawa, K., Nakanishi, T., Tan, M., Fang, H-B., Wang, W-C., Edelman, M., Carlton, D., Sausville, E.A., and Ross, D.D., Clinical Cancer Research, 1/1/2009
• SAHA (Zolinza, vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in Balb/c nude mice  
  Shankar, S., Davis, R., Singh, K.P., Kurzrock, R., Ross, D.D., Srivastava, R.K., Mol Cancer Therapeutics, 1/1/2009
• The 44 kDa Pim-1 kinase phosphorylates BCRP/­ABCG2 and promotes its drug resistant activity in human prostate cancer cells  
  Xie, Y., Xu, K., Linn, D., Nakanishi, T., Ross, D.D., Chen, H., Fazli, L., Gleave, M.E., and Qiu, Y, J Biol Chem, 1/8/2008
• Progesterone Receptor Isoforms, PRA and PRB, Differentially Regulate Expression of the Breast Cancer Resistance Protein (BCRP) in Human Placental Choriocarcinoma BeWo ...  
  Wang H, Lee EW, Zhou L, Leung PC, Ross D, Unadkat JD, Mao Q, Mol Pharmacol, 1/1/2008
• Palliative and End-of-Life Care for Medical Residents  
  Ross, D.D. and Wolfsthal, S, MedEdPORTAL, 1/1/2007
• Family Perspectives on Communication With Healthcare Providers During End-of-Life Cancer Care  
  Royak-Schaler, R., Gadalla, S.M., Lemkau, J.P., Ross, D.D., Alexander, S., Scott, D., Oncology Nursing Forum, 1/1/2006
• Readers respond to ‘balancing evidence-based medicine and cultural competence in the quest to end healthcare disparities’  
  Royak-Schaler R, DeYoung C, Khakpour N, Ross D, Tkaczuk K, Gadalla S, MedGenMed, 1/1/2006
• Cyclosporin A, tacrilimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan  
  Gupta, A., Vethanaygam, R.R., Herbert, M.F., Thummel, K.E., Unadkat, J.D., Ross, D.D., and Mao, Q, Cancer Chemotherapy and Pharmacology, 1/1/2006
• Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP ex...  
  Nakanishi, T., Shiozawa, K., Hassel, B.A., and Ross, D.D., BLOOD, 1/1/2006
• Novel 5’ UTR variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-spe...  
  Nakanishi, T., Bailey-Dell, K., Hassel, B., Shiozawa, K., Sullivan, D., Turner, J., Ross, D.D., Cancer Research, 1/1/2006
• Thapsigargin resistance in human prostate cancer cells  
  O’Neill, J., Velalar, C.N., Lee, D.I., Zhang, B., Nakanishi, T., Tang, Y., Selaru, F, Ross, D., Meltzer, S.J., Hussain, A, Cancer, 1/1/2006
• Alterations in the Mitochondrial Proteome of Adriamycin Resistant MCF-7 Breast Cancer Cells  
  Strong, R., Nakanishi, T., Ross, D., Fenselau. C., Journal of Proteome Research, 1/1/2006
• The ErbB3 binding protein Ebp1 suppresses Androgen Receptor mediated gene transcription and tumorigenesis of prostate cancer cells  
  Zhang, Y., Wang, X-W., Jelovac, D., Nakanishi, T., Yu, M-H., Akinmade, D., Goloubeva, O., Ross, D.D., Brodie, A. and Hamburger, A.W., PNAS, Epub, 1/30/2005
• Plasma Pharmacokinetics and Tissue Distribution of the Breast Cancer Resistance Protein (BCRP) Inhibitor Fumitremorgin C (FTC) in SCID Mice Bearing T8 Tumors  
  Garimella TS, Ross DD, Eiseman JL, Mondick J, Joseph E, Nakanishi T, Bates SE, Bauer KS, Cancer Chemotherapy and Pharmacology, 1/1/2005
•  
  Bauer KS, Karp JE, Garimella TS, Wu S, Tan M, and Ross DD, Leukemia Research, 1/1/2005
• Long-term Evaluation of New and Required Coursework in Palliative and End-of-Life Care for Medical Students  
  Ross, DD, Shpritz, D, Hull, MM, Goloubeva, O, J Palliat Med, 1/1/2005
• Interactive effects of HDAC inhibitors and TRAIL in multiple myeloma  
  Fandy T, Shankar S, Singh TR, Ross DD, Sausville E, Srivastava RK, Neoplasia, 1/1/2005
• Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: Involvement of both death receptor and mitochondrial pathways  
  Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK, International Journal of Molecular Medicine, 1/1/2005
• Join now to see all

Books/Book Chapters

• Resistance of Targeted Anti-Cancer Therapeutics 
  Chapter: Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance 
  Natarajan, K., Baer, M.R., Ross, D.D.Editors: Thomas Efferth.Springer, New York2014
• Acute Myelogenous Leukemia 
  Chapter: Drug Resistance Transporters in AML 
  Page 163 - 173Ross, D.D.Editors: Karp JE.Humana Press, Totowa, NJ2007

Abstracts/Posters

• Phospho-CREB binds directly and specifically to the E1b alternative promoter of mouse Bcrp1/Abcg2 and enhances its transcription
  Xie, Y., Natarajan, K., and Ross, D.D., 8th Annual North American ABC Workshop, Frederick Cancer Research Center, 1/28/2011
• Formative evaluation of Experiential, Competency-Based Palliative and End-Of-Life Care Training For Internal Medical Residents and Medical Oncology Fellows
  Ross, DD, Shpritz, DW, Wolfsthal, SD, Zimrin, AB, Keay, TJ, Fang, H, Schuetz, C, Stapleton, LM, and Weissman, DE, AACE 45th Annual Meeting, J. Cancer Ed, 45th Annual Meeting of the American Association for Cancer Education, 1/9/2011
• Maximal Power Design and Analysis of Drug Combination Studies: Applications to Vorinostat with Cytosine Arabinoside and Etoposide and Other Combination Studies
  Fang, H, Ross DD, Tan, M, AACR 100th Annual Meeting, Washington, DC, 1/1/2010
• Implementation of Experiential, Competency-Based Palliative and End-Of-Life Care Training For Internal Medical Residents and Medical Oncology Fellows
  Ross, DD, Shpritz, DW, Wolfsthal, SD, Zimrin, AB, Keay, TJ, Fang, H, Schuetz, C, Stapleton, LM, and Weissman, DE, AACE 44th Annual Meeting, J. Cancer Ed, 1/1/2010
• Competency Based Experiential Training in Palliative and End-of-Life Care for Internal Medical Residents and Medical Oncology Fellows
  Wolfsthal, S.D., Ross, D.D., Shpritz, D.W., Zimrin, A.B., Keay, T.J., Goloubeva, O.G., Stapleton, L.M., and Weissman, D.E., Alliance for Academic Medicine (AAIM), 1/30/2008
• The 44 kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug resistant activity in human prostate cancer cells
  Yingqiu Xie, Kexin Xu, Douglas Linn, Zhiyong Guo, Takeo Nakanishi, Douglas D. Ross, Yun Qiu, 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 1/12/2008
• Inhibition of HER2 and HER3 phosphorylation can diminish tumor propagating breast cancer cells in vitro and prevent tumor repopulation in NOD/SCID mice
  Saranya Chumsri, Takeo Nakanishi, Pornima Phatak, Brian Leyland-Jones, Douglas D. Ross, Nazanin Khakpour, Anne W. Hamburger, Angelika M. Burger, 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 1/12/2008
• Progress on Implementing a Strategy for Experiential, Competency-Based Palliative and End-of-Life Care Training for Internal Medical Residents and Medical Oncology Fel...
  Ross, D.D., Shpritz, D.W., Wolfsthal, S.D., Zimrin, A.B., Keay, T.J., Goloubeva, O.G., Stapleton, L.M., and Weissman, D.E., American Association for Cancer Education, J. Cancer Ed, 1/1/2008
• Phase I Trial of Vorinostat Combined with Cytarabine and Etoposide in Patients (pts) with Advanced Acute Leukemia and High-Risk Myelodysplastic Syndromes
  Gojo, I, Tan, MT, Shiozawa, K, Nakanishi, T, Burger, AM, Burgess, CL, Egorin, MJ, Baer, MR, Tidwell, ML Srivastava, R, Carrier, F, Scardina, A, Espinoza-Delgado, I, an..., Blood (ASH Annual Meeting Abstracts), 1/1/2008
• Drug efflux through Breast Cancer Resistance Protein (BCRP) is a mechanism of resistance to the insulin-like growth factor receptor/insulin receptor inhibitor BMS-536924
  Haluska, P., Carboni, J.M., Asmann, Y.W., Ten Eyck, C., Attar, R.M., Tibodeau, J.D., Hou, X., Ross, D.D., Kaufmann, S.H., Gottardis, M.M., Erlichman, C, San Antonio Breast Cancer Symposium, 1/1/2008
• Alternative promoter activity of the human breast cancer resistance protein (BCRP/ABCG2) gene in drug-resistant cells
  Nakanishi T, Natarajan, K, Atchison S, Ross DD, 98th Annual Meetings of AACR, Los Angeles, CA, 1/1/2007
• Identification and characterization of the major alternative promoter controlling Bcrp1 expression in the mouse intestine
  Natarajan K, Nakanishi T, Bauer KA, Ross DD, 98th Annual Meetings of AACR, Los Angeles, CA, 1/1/2007
• Overexpression of HER2/Neu in breast cancer cell lines is associated with an increased side population, presence of ABC transporters, and clonogenicity
  Chumsri S, Nakanishi T, Natarajan K, Phatak P, Hamburger AW, Ross DD, Burger AM, 98th Annual Meetings of AACR, Targ Oncol, Los Angeles, CA, 1/1/2007
• Maximum power experimental design and combination index surface analysis for evaluating interactions of drug combinations, with applications to suberoylanilide hydroxa...
  Fang, H-B, Nakanishi T, Sausville E, Ross DD, Tan M, 98th Annual Meetings of AACR, Los Angeles, CA, 1/1/2007
• Strategy for experiential, competency-based palliative and end-of-life care training for internal medicine residents and medical oncology fellows
  Ross, D.D., Shpritz, D.W., Wolfsthal, S.D., Zimrin, A.B., Keay, T.J., Goloubeva, O.G., Stapleton, L.M., Weissman, D.E., J. Cancer Ed, 1/1/2007
• BCRP expression is functionally upregulated by epidermal growth factor receptor (EGFR, ErbB1)-mediated signaling in human ovarian cancer cell lines, but not in human b...
  Nakanishi T, Shiozawa K, Hamburger AW, Ross DD, 97th Annual Meetings of AACR, Washington, DC, 1/1/2006
• Schedule Dependent Synergy of Suberoylanilide Hydroxamic Acid (SAHA or Vorinostat) in Combination with Cytarabine (ara-C) and Etoposide in HL-60 Human Acute Myeloid Le...
  Shiozawa K, Nakanishi T, Tan M, Fang HB, Edelman MJ, Gojo I, Sausville EA, and Ross DD, 97th Annual Meetings of AACR, Washington, DC, 1/1/2006
• A Novel Statistical Method using Uniform Measures for Evaluating Synergy, Antagonism or Additivity of Drug Combinations, with Applications to Suberoylanilide Hydroxami...
  Fang HB, Shiozawa K, Sausville EA, Ross DD, and Tan M, 97th Annual Meetings of AACR, Washington, DC, 1/1/2006
• Training Program In Palliative And End-Of-Life Care For Internal Medicine Residents At An American Medical School
  Ross DD, Shpritz D, and Wolfstahl SD, European Association for Cancer Education, Birmingham, UK, 1/1/2005
• Mandatory Web Based End-Of-Life Care Training Program For Internal Medicine Residents – Evaluation Of Our Experience With Resident Classes of 2005, 2006, and 2007
  Ross DD, Goloubeva O, Shpritz D, and Wolfstahl SD, 39th Annual Meetings of the American Association for Cancer Education, Cincinnati, OH, 1/1/2005
• Evaluation of required postgraduate palliative care training for internal medicine residents
  Ross DD, Shpritz D, Alexander CS, Carter K, Edelman MJ, Friedley N, Hemani A, Keay TJ, Roy SC, Silverman H, Tasker DJ, Timmel D, Schwartz J, Wolfsthal S, J Cancer Education supplement, 1/1/2004
• Adult tissue-derived side population (SP) cells in the pancreas, liver and bone marrow of the rhesus macaque
  Poliakova L, Pirone A, Farese A, Farney A, Ross D, MacVittie T, 6th International Congress of the Cell Transplant Society, 1/1/2003
• Evaluation of required coursework in palliative and end-of-life care for medical students
  Ross D.D., Shpritz D., Hull M., Goloubeva O, Proceedings of the American Association of Cancer Education, 1/1/2003
• Communication issues in palliative and end-of-life care
  Royak-Schaler R., Ross D.D., Hau­s­man K., Tarzian A., Carter K., Scott D.A., Alex­an­der C.S., Proceedings of the American Association of Cancer Education, 1/1/2003
• Evaluation of a web-based course in end-of-life care for internal medicine residents
  Ross D.D, Shpritz D., Alex­an­der C.S., Carter K., Edel­man M.S., Friedley N., He­mani A., Keay T., Roy S., Silver­man H., Tasker D., Timmel D., Wolf­sthal S, Proceedings of the American Association of Cancer Education, 1/1/2003
• Join now to see all

Lectures

• Breast Cancer Resistance Protein (BCRP; ABCG2): Review, Regulation and Role in Resistance 
  Kanazawa, Japan - 1/24/2014
• Implementation of Competency-based Palliative Care Practices at the UMGCC 
  Baltimore, MD - 1/22/2010
• Managing requests for medically ineffective care 
  Baltimore, MD - 1/8/2010
• Breast Cancer Resistance Protein (BCRP/ABCG2): Impact on Cancer Treatment and Outcomes 
  Detroit, MI - 1/13/2008
• Palliative and end-of-life issues for medical practitioners and the public 
  1/26/2007
• BCRP/ABCG2 and Hematologic Malignancies 
  1/20/2007
• Vorinostat Combined with Cytarabine and Etoposide for Treatment of Refractory Acute Leukemias, MPDs and MDS 
  Atlanta, GA - 1/10/2007
• Clinical and Preclinical Studies of Vorinostat Combined with Cytarabine or Etoposide for Treatment of AML 
  Chicago, IL - 1/4/2007
• Medical doctors and burnout 
  1/3/2007
• Cancer Stem Cells as Novel Therapeutic Targets – Role of BCRP/ABCG2 
  Baltimore, MD - 1/16/2006
• Research Activities in Experimental Therapeutics at the Cancer Center 
  Baltimore, MD - 1/13/2006
• Pain Management Update – 2006 
  Ellicott City, MD - 1/11/2006
• Preclinical Studies of Vorinostat Combined With Cytarabine or Etoposide for Treatment of AML 
  Atlanta, GA - 1/5/2006
• Update of the function of the Breast Cancer Resistance Protein (BCRP/ABCG2) in health and disease 
  Baltimore, MD - 1/4/2006
• What really matters in the end? The impact of law versus other factors (financing, politics) on end-of-life care 
  Baltimore, MD - 1/1/2006
• Role of the ABC Transporter Breast Cancer Resistance Protein (ABCG2) in Health and Disease 
  Baltimore, MD - 1/24/2005
• Translating Discovery into Delivery: the Essential Role of Education 
  Cincinnati, OH - 1/17/2005
• The Challenge of End-of-Life Patient Care 
  Baltimore, MD, 2002, 2003, 2004, 2005 - 1/13/2005
• ABCG2 (BCRP) and Its Role in Drug Absorption, Distribution, Metabolism, and Excretion (ADME) and Drug Resistance 
  Parsippany, NJ - 1/7/2005
• Role of the ABC transporter breast cancer resistance protein (BCRP, ABCG2) in drug disposition 
  Kanazawa, Japan - 1/18/2004
• Function and clinical relevance of BCRP in normal physiology and in cancer drug resistance 
  Tampa, FL; Chicago, IL; Tokyo, Japan - 1/15/2004
• Multidrug resistance and cancer: the role of BCRP 
  Baltimore, MD - 1/9/2004
• Overview and Update on the Role of BCRP/ABCG2 in Multidrug Resistance 
  Bethesda, MD - 1/1/2004
• ATP-Binding Cassette (ABC) transport proteins: From genetic disease to multidrug resistance 
  Detroit, MI - 1/13/2003
• Function and Clinical Relevance of BCRP as a Drug Resistance Protein 
  Amsterdam, the Netherlands; Detroit, MI - 1/12/2003
• Join now to see all

Other

• Thesis title: "Effects of Colony Stimulating Factor (CSF) on Macromolecular Synthesis in Mouse Bone Marrow Cultures" 
  Emory University
  Atlanta, GA - 1/1/1972